Application of Cetrorelix - A GnRH-antagonist in reproductive medicine

Objective: The introduction of GnRH antagonists into clinical practice has changed ovarian stimulation therapy prior to IVF-or ICSI-treatment dramatic ally. GnRH antagonists effectively suppress the premature LH surge. Methods: Cetrorelix - the first GnRH antagonist registered for clinical use - can be given daily (0.25 mg) or as single dose of 3 mg, preventing prema ture LH-surge for at least 4 days. Until today on 1500 patients have been a nalysed. Results: Pregnancy Fates using the GnRH antagonist are similar compared wit h the success rates achieved with the standard GnRH agonist long-protocol. Conclusion: However duration of treatment is significantly shorter and the incidence of ovarian hyperstimulation syndrome is reduced with Cetrorelix. Until today the effects of Cetrorelix have not been studied in poor respond ers and/or patients with polycystic ovary syndrome (PCOS).